Endurant Capital Management LP - PROTEOSTASIS THERAPEUTICS IN ownership

PROTEOSTASIS THERAPEUTICS IN's ticker is PTI and the CUSIP is 74373B109. A total of 87 filers reported holding PROTEOSTASIS THERAPEUTICS IN in Q1 2019. The put-call ratio across all filers is 0.50 and the average weighting 0.0%.

Quarter-by-quarter ownership
Endurant Capital Management LP ownership history of PROTEOSTASIS THERAPEUTICS IN
ValueSharesWeighting
Q4 2019$108,000
-34.5%
47,400
-63.7%
0.03%
-47.7%
Q1 2019$165,000
-92.6%
130,600
-72.3%
0.06%
-92.2%
Q1 2018$2,242,000
-20.7%
472,012
-2.7%
0.84%
-3.0%
Q4 2017$2,828,000485,0120.86%
Other shareholders
PROTEOSTASIS THERAPEUTICS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 3,804,027$17,803,0002.95%
HARBOURVEST PARTNERS LLC 440,627$2,062,0000.89%
NEA Management Company, LLC 3,556,778$16,646,0000.61%
Rock Springs Capital Management LP 450,000$2,106,0000.11%
Bain Capital Public Equity Management, LLC 263,498$1,233,0000.07%
ELEMENT CAPITAL MANAGEMENT LLC 65,973$309,0000.06%
Hillhouse Capital Management 865,923$4,053,0000.06%
SABBY MANAGEMENT, LLC 125,151$586,0000.04%
Marshall Wace North America L.P. 684,124$3,421,0000.02%
FNY Partners Fund LP 20,127$94,0000.02%
View complete list of PROTEOSTASIS THERAPEUTICS IN shareholders